Table 2 Clinical variables across groups.
From: Characterization of basal ganglia volume changes in the context of HIV and polysubstance use
HIV-/POLY− (n = 34) | HIV−/POLY + (n = 27) | HIV + /POLY− (n = 17) | HIV + /POLY + (n = 15) | P-value | |
|---|---|---|---|---|---|
Estimated duration of HIV infection years (SD) | –- | –- | 21.53 (8.7) | 21.27 (8.1) | 0.930 |
AIDS (CD4 < 200 cells/mm3) | –- | –- | 41.2 | 73.3 | 0.067 |
Current CD4 count (SD) | –- | –- | 762.18 (304.2) | 642.60 (314.0) | 0.284 |
CD4 nadir (SD) | –- | –- | 322.65 (282.8) | 133.07 (204.6) | 0.037 |
HIV viral load (n < 20 copies/mL) | –- | –- | 15 | 13 | 0.471 |
Current or past exposure to EFV (n) | –- | –- | 11 | 11 | 0.779 |
ART adherence lifetime (SD) | – | – | 92.82 (9.8) | 84.40 (13.3) | 0.054 |
